Werewolf Therapeutics, Inc.: BALYASNY ASSET MANAGEMENT L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. disclosed a stake exceeding 5% in Werewolf Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005044). The passive-investor disclosure signals a meaningful institutional position in the clinical-stage biotech, which develops engineered cytokine therapies for cancer. The exact share count and percentage were not specified in the filing headline, and the 13G indicates the position was not taken with control intent. Investors will watch for further 13G amendments or 13D filings that could clarify Balyasny's intentions and any subsequent changes in the stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Werewolf Therapeutics, Inc., Balyasny Asset Management L.P.